Overview

Glycan Biosciences has combined Chemistry and Biology platforms to produce a new class of biologically active glycoconjugates called Glycanics™. A select group of Glycanics™ disrupt protein-protein interactions that lead to inflammatory diseases, and represent a new class of anti-inflammatory drugs. Other Glycanics™ stabilise proteins, extending their life in the body, whereas yet other types of Glycanics™ prevent viral and bacterial infection of cells. Our IP allows tailoring of Glycanics™ to display the desired activity for the disease targeted. Thus we can generate a pipeline of drugs for different disease indications. Glycan Biosciences’ first generation Glycanics™ target chronic inflammatory diseases.

Glycan Biosciences Pty Ltd. was founded in 2006 by inventors Deirdre Coombe and Warren Kett, then of Curtin University of Technology, Perth, Western Australia.

Glycan Biosciences has built an Intellectual Property Portfolio covering : i) Glycanics™ manufacture, ii) particular Glycanic™ structures, iii) Glycanic™ binding-sites on target proteins and iv) the application of Glycanics™ to specific diseases.

The Company has an experienced Board and Management team with broad expertise in technology and product development as well as in growing successful biotechnology start-ups. Glycan Biosciences has supportive investors including Venture Capital, corporate and angel investors.